Benzinga - by Avi Kapoor, Benzinga Staff Writer.
U.S. stock futures were mixed this morning, with the Dow Jones futures trading almost flat on Monday.
Shares of The Cigna Group (NYSE: CI) shares rose sharply in pre-market trading. Cigna has withdrawn from its proposed merger with Humana Inc. (NYSE: HUM).
The deal, poised to create a colossal entity in the industry with an estimated $140 billion, fell through due to disagreements over financial terms.
Cigna shares climbed 11.6% to $288.88 in pre-market trading.
Here are some big stocks recording gains in today’s pre-market trading session.
- Macy's, Inc. (NYSE: M) shares jumped 19.1% to $20.71 in pre-market trading. An investor consortium has tabled a $5.8 billion bid to acquire Macy's, in an attempt to privatize the iconic department store chain.
- NaaS Technology Inc. (NASDAQ: NAAS) surged 14.9% to $2.39 in pre-market trading. NaaS Technology recently announced termination of proposed Charge Amps acquisition.
- bluebird bio, Inc. (NASDAQ: BLUE) gained 10.8% to $3.170 in pre-market trading after the company said updated data from the company’s gene therapy program in transfusion-dependent beta-thalassemia were presented today at the 65th ASH Annual Meeting & Exposition.
- Oatly Group AB (NASDAQ: OTLY) climbed 8.1% to $1.20 in pre-market trading after declining around 3% on Friday.
- Kohl's Corporation (NYSE: KSS) gained 6.3% to $26.20 in pre-market trading after gaining 3% on Friday.
- Nordstrom, Inc. (NYSE: JWN) rose 5.4% to $17.24 in pre-market trading.
- Snap Inc. (NYSE: SNAP) rose 4.6% to $15.79 in pre-market trading.
- MorphoSys AG (NASDAQ: MOR) gained 4% to $7.33 in pre-market trading as the company presented comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib at 65th American Society of Hematology Annual Meeting.
- Pinterest, Inc. (NYSE: PINS) rose 3.2% to $36.03 in pre-market trading.
- Humana Inc. (NYSE: HUM) gained 2.3% to $492.89 in pre-market trading. Cigna has withdrawn from its proposed merger with Humana.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Don’t forget to check out our premarket coverage here
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.